Game-changing solution offers rapid quantitation of over a thousand lipids, and signals the arrival of next-generation lipidomics
Lipidomics researchers currently rely on fragmented mass spectrometry hardware and software systems for lipid analysis, resulting in inefficient workflows that cannot be reliably scaled up or used by a non-expert. Furthermore, lipid analysis typically involves complicated sample preparation techniques and challenging sample analysis, with many isobaric and near isobaric interferences that can be particularly problematic for lipid identification and accurate quantitation. The all-in-one Lipidyzer Platform includes proprietary SelexION™ Technology to overcome these lipid separation challenges, and delivers highly accurate and sensitive quantitation across many common lipid classes. Sample preparation is simplified and standardized with sample preparation kits that have been optimized by leading lipidomics experts, improving the reproducibility and reliability of research data, as well as saving time.
"This is the first integrated scientific analyzer that’s dedicated to quantitative lipid profiling and it will play a crucial role in making next-generation lipidomics available to the broader scientific community," said Aaron Hudson, Senior Director of Academic and Clinical Research Business of SCIEX. "This platform does more than provide data; it’s a game-changing solution, as it actually delivers actionable biological information that can be shared through our online cloud-based tools, helping to advance lipid-based disease research."
The sample-to-biology platform includes Metabolon’s comprehensive custom-developed software for relevant interpretation and visualization of data from a biology and disease-significance perspective. Metabolon, a leader in the science of metabolomics since 2000, also provides expert consultancy services to help users with data analysis and interpretation.
"The unique ability of the Lipidyzer to generate quantitative, specific and complete lipidomic data allows for an accurate mapping of the results to lipid metabolic pathways," commented Steve Watkins, Ph.D., Chief Technology Officer at Metabolon. "Once researchers have this technology in their hands, I am sure our knowledge of the fundamental role of lipids in many aspects of health and disease will expand tremendously. We’re proud to have co-developed the Lipidyzer Platform; it provides a real advance in lipidomics research."